NKGen Biotech, Inc. Common Stock
Price Action
Technical Summary
CONSOLIDATINGNKGen Biotech, Inc. Common Stock is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 83), indicating clear outperformance against the broad market. Earnings growth of 84% provides fundamental context to the price action. Investors should exercise caution due to high volatility (265% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.07 | -9.09% | BELOW |
| 50 SMA | $0.08 | -26.29% | BELOW |
| 100 SMA | $0.06 | -7.12% | BELOW |
| 150 SMA | $0.06 | -2.91% | BELOW |
| 200 SMA | $0.09 | -36.64% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NKGN in an uptrend right now?
NKGN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is NKGN overbought or oversold?
NKGN's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.
Is NKGN outperforming the market?
NKGN has a Relative Strength (RS) Rating of 83 out of 99. Yes, NKGN is a market leader, outperforming 83% of all stocks over the past 12 months.
Where is NKGN in its 52-week range?
NKGN is trading at $0.06, which is 13% of its 52-week high ($0.46) and 13% above its 52-week low ($0.00).
How volatile is NKGN?
NKGN has a Beta of 2.99 and 52-week volatility of 265%. It's more volatile than the S&P 500 - expect bigger swings.